An FDA advisory panel has voted to allow the compounding of tirzepatide and semaglutide, major GLP-1 agonists used for weight loss and diabetes, while rejecting a petition for a third peptide. This decision is a significant victory for the compounding industry and patients seeking lower-cost alternatives to branded drugs like Mounjaro and Zepbound, though it bypasses standard safety approvals.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.